Bisphosphonates and other bone agents for breast cancer.

about

Stromal cells in breast cancer as a potential therapeutic target.Osteoporosis and musculoskeletal complications related to therapy of breast cancer Multimodal Treatment of Bone Metastasis-A Surgical Perspective

P2860

Q55016792-10BE56CA-2CBC-4233-9FB3-7E0C5074EC0C Q57108686-8427FE4A-41EF-4899-90D0-D76FB077121F Q57652753-F2FB9EF8-DE77-406F-9C6F-79651ECE7D2A

P2860

Bisphosphonates and other bone agents for breast cancer.

Item

http://www.wikidata.org/entity/Q47693752

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Bisphosphonates and other bone agents for breast cancer.

@en

Bisphosphonates and other bone agents for breast cancer.

@nl

type

Item

label

Bisphosphonates and other bone agents for breast cancer.

@en

Bisphosphonates and other bone agents for breast cancer.

@nl

prefLabel

Bisphosphonates and other bone agents for breast cancer.

@en

Bisphosphonates and other bone agents for breast cancer.

@nl

P1476

Bisphosphonates and other bone agents for breast cancer

@en

P2093

Annabel Goodwin

http://www.w3.org/2001/XMLSchema#string

Brent O'Carrigan

http://www.w3.org/2001/XMLSchema#string

Martin R Stockler

http://www.w3.org/2001/XMLSchema#string

Matthew Hf Wong

http://www.w3.org/2001/XMLSchema#string

Melina L Willson

http://www.w3.org/2001/XMLSchema#string

Nick Pavlakis

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonates and other bone agents for breast cancer

Bisphosphonates for breast cancer

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

Measuring inconsistency in meta-analyses

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Practical methods for incorporating summary time-to-event data into meta-analysis

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

P304

CD003474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/14651858.CD003474.PUB4

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29082518

http://www.w3.org/2001/XMLSchema#string

P932

6485886

http://www.w3.org/2001/XMLSchema#string

Bisphosphonates and other bone agents for breast cancer.

about

P2860

P2860

Bisphosphonates and other bone agents for breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932